title: PARK2 orchestrates cyclins to avoid cancer.
abstract: Proper control of cyclin-dependent kinases ensures coordinated cell cycle progression and guards against tumorigenesis. A new study identifies the PARK2 E3 ubiquitin ligase as an important coordinator of G1/S-phase cyclin turnover and explains how mutations targeting this key cell cycle regulatory node contribute to a range of cancers.
authors.affiliation: 1] Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic. [2] Danish Cancer Society Research Center, Copenhagen, Denmark.
authors.forename: Jiri
authors.initials: J
authors.lastname: Bartek
authors.affiliation: Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Hodny
mesh_terms: D000818:Animals; D002453:Cell Cycle; D019938:Cyclin D1 / Q000378:metabolism*; D019927:Cyclin E / Q000378:metabolism*; D051358:Cyclin-Dependent Kinase 4 / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015513:Oncogene Proteins / Q000378:metabolism*; D044767:Ubiquitin-Protein Ligases / Q000235:genetics*
chemical_list: C530104:CCND1 protein, human; C475820:CCNE1 protein, human; D019927:Cyclin E; D015513:Oncogene Proteins; D019938:Cyclin D1; D044767:Ubiquitin-Protein Ligases; C111567:parkin protein; C495900:CDK4 protein, human; D051358:Cyclin-Dependent Kinase 4